| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microbiology | 21 | 2020 | 72 | 5.820 |
Why?
|
| Periodicals as Topic | 23 | 2020 | 1432 | 2.880 |
Why?
|
| Microbiological Techniques | 7 | 2019 | 102 | 2.800 |
Why?
|
| Microbial Sensitivity Tests | 15 | 2023 | 1877 | 2.790 |
Why?
|
| Clinical Laboratory Techniques | 8 | 2020 | 738 | 2.420 |
Why?
|
| Editorial Policies | 9 | 2020 | 451 | 2.000 |
Why?
|
| Communicable Diseases | 8 | 2020 | 880 | 1.750 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2019 | 783 | 1.560 |
Why?
|
| Laboratories | 3 | 2019 | 463 | 1.530 |
Why?
|
| Bacteriological Techniques | 5 | 2019 | 277 | 1.520 |
Why?
|
| Bacterial Infections | 7 | 2022 | 1401 | 1.450 |
Why?
|
| Reagent Strips | 2 | 2019 | 39 | 1.400 |
Why?
|
| Respiratory Tract Infections | 9 | 2022 | 961 | 1.310 |
Why?
|
| Automation, Laboratory | 2 | 2019 | 101 | 1.290 |
Why?
|
| Vibrio Infections | 2 | 2016 | 33 | 1.110 |
Why?
|
| Vibrio parahaemolyticus | 2 | 2016 | 39 | 1.100 |
Why?
|
| Paramyxoviridae Infections | 4 | 2010 | 55 | 1.090 |
Why?
|
| Societies, Scientific | 9 | 2020 | 220 | 1.070 |
Why?
|
| Anti-Bacterial Agents | 15 | 2023 | 7181 | 1.070 |
Why?
|
| Water Microbiology | 2 | 2016 | 117 | 1.060 |
Why?
|
| Metapneumovirus | 5 | 2010 | 23 | 1.000 |
Why?
|
| Lacerations | 2 | 2016 | 144 | 0.990 |
Why?
|
| Gastroenteritis | 2 | 2018 | 245 | 0.980 |
Why?
|
| Piperacillin | 1 | 2023 | 41 | 0.950 |
Why?
|
| Awards and Prizes | 2 | 2019 | 375 | 0.940 |
Why?
|
| Wound Infection | 2 | 2016 | 242 | 0.940 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 2 | 2015 | 28 | 0.890 |
Why?
|
| Cartoons as Topic | 5 | 2021 | 17 | 0.870 |
Why?
|
| Viruses | 4 | 2016 | 374 | 0.760 |
Why?
|
| Journal Impact Factor | 6 | 2016 | 156 | 0.750 |
Why?
|
| Bacteria | 5 | 2019 | 2114 | 0.740 |
Why?
|
| Public Health Administration | 2 | 2020 | 240 | 0.710 |
Why?
|
| Staphylococcus | 1 | 2020 | 155 | 0.700 |
Why?
|
| Escherichia coli Infections | 3 | 2015 | 532 | 0.690 |
Why?
|
| Serologic Tests | 2 | 2019 | 374 | 0.680 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3133 | 0.630 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3240 | 0.630 |
Why?
|
| Virus Diseases | 4 | 2016 | 711 | 0.620 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2011 | 459 | 0.620 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2020 | 224 | 0.610 |
Why?
|
| Marketing | 1 | 2019 | 212 | 0.610 |
Why?
|
| Foodborne Diseases | 1 | 2017 | 39 | 0.590 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2022 | 1035 | 0.580 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 468 | 0.580 |
Why?
|
| Phlebotomy | 1 | 2017 | 141 | 0.560 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2018 | 602 | 0.550 |
Why?
|
| T-Lymphocytes, Cytotoxic | 12 | 2000 | 1821 | 0.550 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2017 | 214 | 0.530 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2016 | 87 | 0.520 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 857 | 0.520 |
Why?
|
| Fungi | 3 | 2016 | 327 | 0.520 |
Why?
|
| Carrier State | 5 | 2013 | 518 | 0.510 |
Why?
|
| Anti-Infective Agents | 2 | 2019 | 972 | 0.510 |
Why?
|
| Metagenomics | 1 | 2018 | 428 | 0.500 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2017 | 687 | 0.490 |
Why?
|
| Erythromycin | 2 | 2004 | 120 | 0.480 |
Why?
|
| Influenza, Human | 6 | 2011 | 1479 | 0.470 |
Why?
|
| Publications | 1 | 2016 | 195 | 0.470 |
Why?
|
| Clindamycin | 2 | 2004 | 139 | 0.460 |
Why?
|
| Publishing | 3 | 2020 | 833 | 0.440 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2022 | 4751 | 0.430 |
Why?
|
| Interleukin-2 | 8 | 2000 | 1904 | 0.430 |
Why?
|
| Humans | 105 | 2023 | 744343 | 0.410 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2019 | 503 | 0.390 |
Why?
|
| Burkholderia Infections | 4 | 2013 | 44 | 0.380 |
Why?
|
| Virus Cultivation | 2 | 2009 | 92 | 0.380 |
Why?
|
| Virology | 1 | 2011 | 77 | 0.380 |
Why?
|
| Staphylococcal Infections | 4 | 2012 | 1400 | 0.380 |
Why?
|
| Mycoses | 1 | 2013 | 376 | 0.370 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 2002 | 906 | 0.360 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2018 | 323 | 0.360 |
Why?
|
| Immune System | 1 | 2016 | 805 | 0.360 |
Why?
|
| History, 21st Century | 4 | 2019 | 1534 | 0.360 |
Why?
|
| Clostridium Infections | 2 | 2014 | 548 | 0.360 |
Why?
|
| Cross Infection | 3 | 2014 | 1416 | 0.360 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 1177 | 0.350 |
Why?
|
| Antigens, Viral | 2 | 2010 | 1035 | 0.330 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 465 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 2000 | 1369 | 0.330 |
Why?
|
| Host-Pathogen Interactions | 3 | 2016 | 1477 | 0.320 |
Why?
|
| Cystic Fibrosis | 5 | 2022 | 1177 | 0.310 |
Why?
|
| Genes, Bacterial | 4 | 2013 | 1079 | 0.300 |
Why?
|
| History, 20th Century | 4 | 2019 | 2740 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3597 | 0.270 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 3176 | 0.270 |
Why?
|
| Appendicitis | 1 | 2012 | 645 | 0.260 |
Why?
|
| Abdominal Pain | 1 | 2012 | 1063 | 0.260 |
Why?
|
| Biomedical Research | 3 | 2020 | 3309 | 0.260 |
Why?
|
| Sensitivity and Specificity | 8 | 2020 | 14722 | 0.250 |
Why?
|
| Food Microbiology | 2 | 2017 | 78 | 0.250 |
Why?
|
| Bacteremia | 3 | 2021 | 962 | 0.240 |
Why?
|
| Child | 30 | 2022 | 77709 | 0.240 |
Why?
|
| Education, Medical | 1 | 2016 | 1721 | 0.230 |
Why?
|
| Child, Preschool | 24 | 2016 | 41006 | 0.230 |
Why?
|
| Shiga Toxin | 2 | 2015 | 34 | 0.220 |
Why?
|
| Interferon-gamma | 6 | 2013 | 3206 | 0.220 |
Why?
|
| Burkholderia | 2 | 2013 | 38 | 0.220 |
Why?
|
| Immunoassay | 3 | 2010 | 752 | 0.210 |
Why?
|
| Neoplasms, Experimental | 4 | 1996 | 1276 | 0.210 |
Why?
|
| Infant | 21 | 2016 | 35136 | 0.210 |
Why?
|
| Reverse Transcription | 1 | 2022 | 47 | 0.210 |
Why?
|
| Lymphocyte Activation | 6 | 2002 | 5524 | 0.210 |
Why?
|
| Streptococcus agalactiae | 1 | 2004 | 375 | 0.210 |
Why?
|
| Membrane Glycoproteins | 4 | 2000 | 3768 | 0.210 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 1681 | 0.210 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 289 | 0.200 |
Why?
|
| Antigens, CD | 5 | 2000 | 4026 | 0.200 |
Why?
|
| Laboratory Chemicals | 1 | 2021 | 2 | 0.200 |
Why?
|
| Pneumococcal Vaccines | 3 | 2010 | 391 | 0.190 |
Why?
|
| Pandemics | 4 | 2022 | 8388 | 0.190 |
Why?
|
| Coagulase | 1 | 2020 | 54 | 0.180 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2002 | 291 | 0.180 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2000 | 94 | 0.180 |
Why?
|
| Fusarium | 1 | 2020 | 51 | 0.180 |
Why?
|
| Chromosomes, Fungal | 1 | 2020 | 111 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 17 | 2002 | 6386 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 15076 | 0.170 |
Why?
|
| Interleukin-3 | 3 | 1998 | 444 | 0.170 |
Why?
|
| Leadership | 2 | 2019 | 1357 | 0.170 |
Why?
|
| HLA-B7 Antigen | 1 | 1998 | 48 | 0.170 |
Why?
|
| Leukopoiesis | 1 | 1998 | 56 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 1998 | 1366 | 0.170 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2023 | 1219 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2001 | 4386 | 0.170 |
Why?
|
| Genome, Fungal | 1 | 2020 | 204 | 0.170 |
Why?
|
| Lactobacillus | 1 | 2019 | 189 | 0.160 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2010 | 165 | 0.160 |
Why?
|
| Larva | 1 | 2019 | 519 | 0.150 |
Why?
|
| Infant, Newborn | 12 | 2022 | 25625 | 0.150 |
Why?
|
| Health Policy | 2 | 2020 | 2661 | 0.150 |
Why?
|
| Pseudomonas Infections | 1 | 2022 | 613 | 0.150 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2017 | 16 | 0.150 |
Why?
|
| Equipment Reuse | 1 | 2016 | 41 | 0.140 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2016 | 60 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 389 | 0.140 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2010 | 329 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2017 | 204 | 0.140 |
Why?
|
| Selection, Genetic | 3 | 2017 | 914 | 0.140 |
Why?
|
| Genome, Bacterial | 3 | 2019 | 760 | 0.140 |
Why?
|
| Diarrhea, Infantile | 1 | 2016 | 109 | 0.140 |
Why?
|
| Probiotics | 1 | 2019 | 351 | 0.140 |
Why?
|
| Blood Specimen Collection | 1 | 2017 | 246 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5442 | 0.130 |
Why?
|
| Lung Diseases | 2 | 2011 | 1886 | 0.130 |
Why?
|
| Equipment Contamination | 1 | 2016 | 185 | 0.130 |
Why?
|
| Enterovirus | 2 | 2012 | 64 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 1000 | 0.130 |
Why?
|
| United States | 13 | 2020 | 69872 | 0.130 |
Why?
|
| Pharynx | 2 | 2010 | 413 | 0.130 |
Why?
|
| Infant Formula | 1 | 2016 | 199 | 0.120 |
Why?
|
| DNA, Bacterial | 3 | 2012 | 1465 | 0.120 |
Why?
|
| Bacterial Typing Techniques | 1 | 2015 | 256 | 0.120 |
Why?
|
| Nasopharynx | 3 | 2012 | 379 | 0.120 |
Why?
|
| Adolescent | 16 | 2017 | 85781 | 0.120 |
Why?
|
| Sarcoma, Experimental | 1 | 1994 | 128 | 0.120 |
Why?
|
| Pneumococcal Infections | 2 | 2010 | 497 | 0.120 |
Why?
|
| Reference Standards | 1 | 2017 | 1025 | 0.120 |
Why?
|
| Prevalence | 7 | 2017 | 15226 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2022 | 2902 | 0.110 |
Why?
|
| Streptococcal Infections | 2 | 2010 | 638 | 0.110 |
Why?
|
| Peer Review, Research | 1 | 2016 | 329 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 2 | 2010 | 714 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1799 | 0.110 |
Why?
|
| Respiratory System | 1 | 2016 | 557 | 0.110 |
Why?
|
| Feces | 3 | 2016 | 1401 | 0.110 |
Why?
|
| Animals | 29 | 2019 | 168757 | 0.110 |
Why?
|
| Hand, Foot and Mouth Disease | 1 | 2012 | 25 | 0.110 |
Why?
|
| Taenia | 1 | 2012 | 17 | 0.110 |
Why?
|
| Female | 32 | 2020 | 380194 | 0.110 |
Why?
|
| Diagnostic Services | 1 | 2012 | 34 | 0.110 |
Why?
|
| Taeniasis | 1 | 2012 | 15 | 0.110 |
Why?
|
| Molecular Typing | 1 | 2012 | 106 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7279 | 0.110 |
Why?
|
| Burkholderia cepacia complex | 1 | 2012 | 25 | 0.100 |
Why?
|
| Animal Feed | 1 | 2012 | 110 | 0.100 |
Why?
|
| Meningitis, Viral | 1 | 2012 | 50 | 0.100 |
Why?
|
| Enterotoxins | 1 | 2013 | 368 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 3 | 1994 | 2007 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4982 | 0.100 |
Why?
|
| Enterovirus Infections | 1 | 2012 | 72 | 0.100 |
Why?
|
| Research | 1 | 2020 | 1999 | 0.100 |
Why?
|
| Streptococcus milleri Group | 1 | 2010 | 6 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2012 | 424 | 0.100 |
Why?
|
| Mandatory Reporting | 1 | 2012 | 121 | 0.100 |
Why?
|
| Diarrhea | 2 | 2019 | 1348 | 0.100 |
Why?
|
| Lung Abscess | 1 | 2010 | 42 | 0.090 |
Why?
|
| Sulfamethoxazole | 1 | 2010 | 53 | 0.090 |
Why?
|
| Latent Tuberculosis | 1 | 2013 | 225 | 0.090 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2010 | 28 | 0.090 |
Why?
|
| Hospitals | 1 | 2004 | 3952 | 0.090 |
Why?
|
| Trimethoprim | 1 | 2010 | 91 | 0.090 |
Why?
|
| Lyme Disease | 1 | 2016 | 621 | 0.090 |
Why?
|
| Antibodies, Bacterial | 2 | 2016 | 1470 | 0.090 |
Why?
|
| Bacterial Proteins | 3 | 2013 | 3848 | 0.090 |
Why?
|
| Phylogeny | 4 | 2020 | 2803 | 0.090 |
Why?
|
| Fimbriae Proteins | 1 | 2010 | 134 | 0.090 |
Why?
|
| Inappropriate Prescribing | 1 | 2012 | 202 | 0.090 |
Why?
|
| Boston | 5 | 2012 | 9313 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1995 | 986 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2016 | 1547 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 1320 | 0.080 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2012 | 578 | 0.080 |
Why?
|
| Male | 30 | 2020 | 350118 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2012 | 981 | 0.080 |
Why?
|
| Culture Media | 1 | 2010 | 908 | 0.080 |
Why?
|
| Mice | 24 | 2012 | 81183 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 567 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2000 | 4479 | 0.080 |
Why?
|
| Killer Cells, Natural | 2 | 1995 | 2133 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2016 | 1338 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 1475 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 1994 | 1038 | 0.080 |
Why?
|
| Bacterial Toxins | 1 | 2013 | 931 | 0.080 |
Why?
|
| Th2 Cells | 3 | 2002 | 1061 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 2010 | 338 | 0.080 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2009 | 139 | 0.080 |
Why?
|
| Bronchiolitis, Viral | 1 | 2008 | 74 | 0.070 |
Why?
|
| Transfection | 8 | 1996 | 5892 | 0.070 |
Why?
|
| Mass Screening | 2 | 2020 | 5255 | 0.070 |
Why?
|
| Cytokines | 4 | 2002 | 7322 | 0.070 |
Why?
|
| Fimbriae, Bacterial | 1 | 2007 | 138 | 0.070 |
Why?
|
| Meningococcal Vaccines | 1 | 2007 | 95 | 0.070 |
Why?
|
| Rhinovirus | 1 | 2008 | 187 | 0.070 |
Why?
|
| Immunoconjugates | 3 | 1999 | 901 | 0.070 |
Why?
|
| Nose | 1 | 2010 | 509 | 0.070 |
Why?
|
| Disease Outbreaks | 2 | 2013 | 1772 | 0.070 |
Why?
|
| Th1 Cells | 2 | 2002 | 1057 | 0.070 |
Why?
|
| Bronchiolitis | 1 | 2012 | 458 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 6171 | 0.070 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 944 | 0.070 |
Why?
|
| Pediatrics | 3 | 2020 | 3475 | 0.060 |
Why?
|
| Mice, Knockout | 7 | 2002 | 14557 | 0.060 |
Why?
|
| Lung | 3 | 2017 | 9856 | 0.060 |
Why?
|
| Lincosamides | 1 | 2004 | 4 | 0.060 |
Why?
|
| Dogs | 1 | 2009 | 3912 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 847 | 0.060 |
Why?
|
| Paramyxoviridae | 1 | 2004 | 9 | 0.060 |
Why?
|
| Pneumonia | 1 | 2016 | 2133 | 0.060 |
Why?
|
| Agar | 1 | 2004 | 56 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2000 | 1827 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2008 | 456 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1584 | 0.060 |
Why?
|
| Seasons | 3 | 2006 | 1493 | 0.060 |
Why?
|
| Retrospective Studies | 9 | 2021 | 77449 | 0.060 |
Why?
|
| Haptens | 2 | 2001 | 166 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2010 | 788 | 0.060 |
Why?
|
| Antigens, Bacterial | 2 | 2013 | 1171 | 0.060 |
Why?
|
| Indians, North American | 1 | 2007 | 355 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2000 | 517 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 1265 | 0.060 |
Why?
|
| Inclusion Bodies | 1 | 2004 | 279 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 201 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2019 | 6544 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 40075 | 0.050 |
Why?
|
| Biological Products | 1 | 2012 | 860 | 0.050 |
Why?
|
| Massachusetts | 6 | 2016 | 8663 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2011 | 1940 | 0.050 |
Why?
|
| Hospitalization | 4 | 2012 | 10262 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 712 | 0.050 |
Why?
|
| Meningitis, Bacterial | 1 | 2004 | 218 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 768 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 1998 | 6314 | 0.050 |
Why?
|
| Graft Rejection | 2 | 1999 | 4397 | 0.050 |
Why?
|
| Diffusion | 1 | 2004 | 833 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2010 | 1451 | 0.050 |
Why?
|
| Emergency Service, Hospital | 4 | 2009 | 7659 | 0.050 |
Why?
|
| Antigens, Differentiation | 3 | 1999 | 927 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2004 | 404 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2004 | 367 | 0.050 |
Why?
|
| Laboratory Personnel | 1 | 2020 | 19 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2001 | 158 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 3508 | 0.050 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2002 | 124 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2000 | 329 | 0.050 |
Why?
|
| Cell Line | 3 | 2009 | 15997 | 0.040 |
Why?
|
| Health Personnel | 1 | 2013 | 3218 | 0.040 |
Why?
|
| Office Visits | 1 | 2004 | 598 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2000 | 1157 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2001 | 526 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 862 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2013 | 2425 | 0.040 |
Why?
|
| Health Services | 1 | 2004 | 758 | 0.040 |
Why?
|
| Germinal Center | 1 | 2001 | 377 | 0.040 |
Why?
|
| Hospitals, Pediatric | 2 | 2021 | 1775 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 20947 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2001 | 880 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2000 | 881 | 0.040 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2020 | 502 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 595 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 1993 | 1607 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 12959 | 0.040 |
Why?
|
| Prospective Studies | 7 | 2022 | 53288 | 0.040 |
Why?
|
| Half-Life | 1 | 2017 | 661 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2007 | 4803 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 10180 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 15540 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2022 | 763 | 0.030 |
Why?
|
| Signal Transduction | 2 | 1999 | 23403 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 331 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2001 | 1402 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2022 | 1241 | 0.030 |
Why?
|
| Hospital Units | 1 | 2016 | 141 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2020 | 912 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2012 | 2373 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2006 | 2616 | 0.030 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 3158 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2012 | 40561 | 0.030 |
Why?
|
| Disinfection | 1 | 2016 | 191 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 1998 | 973 | 0.030 |
Why?
|
| Borrelia burgdorferi | 1 | 2016 | 180 | 0.030 |
Why?
|
| Zidovudine | 1 | 2016 | 620 | 0.030 |
Why?
|
| Spleen | 1 | 2000 | 2362 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 3129 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 976 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2000 | 2225 | 0.030 |
Why?
|
| Ligands | 1 | 2000 | 3282 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2019 | 3679 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2000 | 11483 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 1994 | 2085 | 0.030 |
Why?
|
| Botswana | 1 | 2016 | 1040 | 0.030 |
Why?
|
| Prognosis | 2 | 2012 | 29063 | 0.030 |
Why?
|
| Young Adult | 3 | 2013 | 56430 | 0.030 |
Why?
|
| Blood Bactericidal Activity | 1 | 2012 | 126 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 903 | 0.030 |
Why?
|
| Clone Cells | 2 | 1992 | 1692 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3772 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2020 | 4011 | 0.030 |
Why?
|
| Colorimetry | 1 | 2012 | 147 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2017 | 956 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2000 | 4217 | 0.020 |
Why?
|
| Interleukins | 1 | 1995 | 791 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 18111 | 0.020 |
Why?
|
| Adaptation, Biological | 1 | 2011 | 153 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1993 | 520 | 0.020 |
Why?
|
| Eosinophils | 1 | 1995 | 955 | 0.020 |
Why?
|
| Bodily Secretions | 1 | 2010 | 23 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 7 | 1999 | 21827 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2004 | 5021 | 0.020 |
Why?
|
| Carcinoma | 2 | 1993 | 2375 | 0.020 |
Why?
|
| Time | 1 | 2012 | 542 | 0.020 |
Why?
|
| Ampicillin | 1 | 2010 | 139 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Adult | 7 | 2017 | 214055 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 1991 | 258 | 0.020 |
Why?
|
| Mutation | 3 | 2022 | 29786 | 0.020 |
Why?
|
| HIV Infections | 1 | 2016 | 16718 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2011 | 315 | 0.020 |
Why?
|
| Risk Factors | 5 | 2010 | 72290 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2020 | 5456 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1999 | 1838 | 0.020 |
Why?
|
| Lung Neoplasms | 5 | 1996 | 13102 | 0.020 |
Why?
|
| Operon | 1 | 2010 | 363 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 25043 | 0.020 |
Why?
|
| Graft Survival | 1 | 1999 | 3737 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1797 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 1999 | 2725 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 1995 | 1348 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2011 | 1005 | 0.020 |
Why?
|
| Cost of Illness | 2 | 2009 | 1859 | 0.020 |
Why?
|
| Utilization Review | 1 | 2009 | 392 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 9734 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2011 | 509 | 0.020 |
Why?
|
| Cell Separation | 1 | 1993 | 1751 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 13815 | 0.020 |
Why?
|
| Ecosystem | 1 | 2012 | 474 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 1988 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1987 | 177 | 0.020 |
Why?
|
| Tachykinins | 1 | 1987 | 78 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 4665 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20129 | 0.020 |
Why?
|
| Stem Cells | 1 | 2000 | 3567 | 0.020 |
Why?
|
| Ovalbumin | 2 | 1999 | 719 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2009 | 313 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2557 | 0.020 |
Why?
|
| Occupational Health | 1 | 2013 | 809 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 1312 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7880 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 15519 | 0.020 |
Why?
|
| Serotyping | 1 | 2007 | 338 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 1996 | 2494 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1539 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2971 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 1999 | 3110 | 0.020 |
Why?
|
| Epidemics | 1 | 2011 | 523 | 0.020 |
Why?
|
| Proteins | 1 | 2000 | 6103 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.020 |
Why?
|
| Latex Fixation Tests | 1 | 2004 | 32 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 1987 | 390 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 1959 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1998 | 2988 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2886 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 2216 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
| Genomics | 1 | 2019 | 5720 | 0.010 |
Why?
|
| Health Resources | 1 | 2009 | 911 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1987 | 1154 | 0.010 |
Why?
|
| Virulence | 1 | 2007 | 1333 | 0.010 |
Why?
|
| Emergency Medicine | 1 | 2012 | 1207 | 0.010 |
Why?
|
| Leishmania mexicana | 1 | 2002 | 31 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2009 | 2715 | 0.010 |
Why?
|
| Neuropeptides | 1 | 1987 | 942 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2017 | 63114 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 534 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 1616 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6365 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 642 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2016 | 4256 | 0.010 |
Why?
|
| Antigens, T-Independent | 1 | 1999 | 21 | 0.010 |
Why?
|
| OX40 Ligand | 1 | 1999 | 51 | 0.010 |
Why?
|
| Immunotherapy | 2 | 2012 | 4445 | 0.010 |
Why?
|
| Tumor Necrosis Factors | 1 | 1999 | 109 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6489 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 3251 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1999 | 129 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1999 | 484 | 0.010 |
Why?
|
| Length of Stay | 1 | 2012 | 6309 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 867 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1101 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 18029 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 1 | 1996 | 47 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2009 | 2348 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 6459 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 12245 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1996 | 642 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1999 | 523 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 10388 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6622 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 3278 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 1999 | 5974 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 3002 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 13408 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1993 | 184 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1993 | 290 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2009 | 4558 | 0.010 |
Why?
|
| Ganciclovir | 1 | 1993 | 258 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 18370 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12788 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4568 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 1991 | 366 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 4776 | 0.010 |
Why?
|
| Microspheres | 1 | 1993 | 777 | 0.010 |
Why?
|
| Magnetics | 1 | 1993 | 606 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 2460 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1991 | 249 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1998 | 2513 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 3887 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 769 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 7785 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1993 | 802 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 13989 | 0.010 |
Why?
|
| Epitopes | 1 | 1996 | 2571 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1993 | 1147 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1987 | 12072 | 0.010 |
Why?
|
| Neurokinin A | 1 | 1987 | 32 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2186 | 0.000 |
Why?
|
| Immunization | 1 | 1991 | 1256 | 0.000 |
Why?
|
| RNA, Messenger | 2 | 1993 | 13033 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 57776 | 0.000 |
Why?
|
| Algorithms | 1 | 2004 | 13881 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1998 | 19229 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1987 | 2187 | 0.000 |
Why?
|
| Phenotype | 1 | 1999 | 16365 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1991 | 4851 | 0.000 |
Why?
|
| Gene Expression | 1 | 1993 | 7799 | 0.000 |
Why?
|
| Aged | 1 | 2010 | 163280 | 0.000 |
Why?
|
| Middle Aged | 1 | 2010 | 213383 | 0.000 |
Why?
|
| Models, Biological | 1 | 1991 | 9583 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1991 | 9274 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 11124 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 24260 | 0.000 |
Why?
|